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Recombinant proteinAbstract Recombinant protein consisting of an antigen fused to C3d may elicit a more robust
immune response than the antigen alone. The objective of the present study was to clone FimA-
c3d recombinant DNA into pCold-TF vector and successfully express in prokaryotic expression
vector. FimA subunit of type I ﬁmbriae from Salmonella enterica serovar Enteritidis was conjugated
to mouse complement fragment molecule C3d. FimA and FimA-mC3d, FimA-mC3d2 and FimA-
mC3d3 were cloned into the expression vector pCold-TF. Constructions of the recombinants
pCold-TF-ﬁmA with different copies of C3d were conﬁrmed by digestion with restriction enzymes
and sequencing. Soluble fusion proteins of FimA with different copies of C3d were induced by
IPTG and were expressed in Escherichia coli BL21 (DE3) under optimal conditions. The results
showed that the proteins induced from recombinants pCold-TF-ﬁmA, pCold-TF-ﬁmA-mC3d,
pCold-TF-ﬁmA-mC3d2 and pCold-TF-ﬁmA-mC3d3 were 70, 100, 130 and 160 kDa, respectively.
The fusion protein was recognized by rabbit anti-ﬁmbriae polyclonal antibodies, and then visual-
ized by goat anti-rabbit polyclonal antibodies with a chrome appearance by enzyme-subtract inter-
action. The recombinant proteins were separately puriﬁed by Ni-TED (tris-carboxymethyl ethylene
diamine) immobilized metal iron afﬁnity chromatography (IMAC). Finally we conclude that anti-
gen conjugated with mC3d can be functionally expressed in prokaryotic vectors.
ª 2014 Production and hosting by Elsevier B.V. on behalf of Academy of Scientific Research &
Technology.1. IntroductionFimbriae of Salmonella enterica serovar Enteritidis are used
for colonization and invasion into host cells, and have drawn
considerable interest because ﬁmbriae can serve as potential
immunogens against many pathogenic bacteria that colonize
epithelial surfaces [24]. The main ﬁmbriae of the S. enterica
56 H.H. Musa et al.serovar Enteritidis are SEF14, SEF17 and SEF21 composed of
SefA, AgfA and FimA ﬁmbrial proteins, respectively [13].
Fimbria-based vaccines are hypothesized to protect the host
against the adherence of pathogens by blocking the attachment
of organisms to the intestinal mucosa [31]. Recently, scientist’s
interest has revolved around the effecter molecules generated
by the innate response and their role in shaping acquired
immunity [6]. Recombinant protein consisting of an antigen
fused to C3d may elicit a more robust immune response than
the antigen alone. Dempsey et al. [2] demonstrated that a
recombinant protein containing three copies of C3d attached
to the carboxy terminus of hen egg lysozyme (HEL) could eli-
cit a primary immune response at a concentration 10,000-fold
more than that required for the unmodiﬁed HEL protein.
A major bottleneck in structural biology is that many
human proteins are expressed very poorly or are expressed well
but not in soluble forms [14]. These difﬁculties may arise due to
the improper folding of human proteins in Escherichia coli cells,
where they are quickly digested by proteases or accumulated as
inclusion bodies [14]. A number of expression systems have
been developed to overcome this problem, for example, by
coexpressing human proteins with molecular chaperones [21],
expressing them as fusions with maltose-binding protein [4],
glutathione S-transferase [27], or expressing them at low tem-
peratures using cold shock vectors [23]. Heat-shock response
from bacteria to humans has been extensively studied, while
cold-shock response has caught the attention of researchers rel-
atively recently [22]. A major reason why heat shock is exten-
sively studied is because it causes well-deﬁned damage to the
cells, i.e. unfolding or denaturation of proteins. In contrast,
cold shock does not cause such well-deﬁned cellular damage.
Cold-shock response is classically exhibited when an exponen-
tially growing culture is shifted from its optimum growth tem-
perature to a lower temperature [22]. Several cold shock
proteins have been detected not only in E. coli but also in many
other bacteria [17,30,25,10]. Certain aspects of bacterial cold-
shock response such as regulation of expression of CspA homo-
logues have been extensively reviewed [5,9,29,35]. CspA func-
tion was proposed to be an RNA chaperone [35,8]. The CspA
family is essential for E. coli cells to adapt to low temperature
[32,3]. A peptidyl prolyl isomerase (trigger factor-TF), that cat-
alyzes the cis/trans isomerization of peptide bonds N-terminal
to the proline residue was identiﬁed in E. coli. This enzyme is
induced upon cold shock at a modest level after a growth lag
period of 2–3 h, its overexpression leads to enhanced viability
[12]. The objective of the present study was to clone FimA-
c3d recombinant DNA into pCold-TF vector and successfully
express in the prokaryotic expression system.2. Materials and methods
2.1. Strains and vectors
Standard strains of Salmoenlla enterica serovar Enteritidis SD-2,
E. coliDH5a and recombinant protein expression recipient strain
E. coli BL21 (DE3), PCold-TF expression vector and recombi-
nant plasmid pUC-mC3d, pUC-mC3d2 and pUC-mC3d3 and
Salmonella Enteritidis -type pilus polyclonal (rabbit) were pre-
served in our laboratory. Primers were synthesized by Shanghai
Gene Core Biotechnology Co., Ltd., and pMD18-T. Simple vec-
tor was purchased from Takara Biotechnology Co., Ltd.2.2. Reagents
Restriction enzymes NdeI, BamHI, BglII and T4 DNA ligase
were purchased from NEB’s, Amp (Ampicillin) and Expand
High Fidelity PLUS PCR System was purchased from the
Roche Company, Puriﬁcation of Polyhistidine-Tagged Pro-
teins (ProteinsNi-TED2000) were purchased fromMACHE-
REY-NAGE company, DNA marker and lysozyme were
purchased from the Takara Company, High molecular weight
marker and Pre-stained low molecular weight marker were
purchased from the Fermentas Company, 3,30-diaminobenzi-
dine (3,30-diamino benzidine, DAB) and agarose gel DNA
extraction kit (centrifugal columnar) were purchased from
the BBI (Bio basic Inc.) company, Isopropyl-b-D-thiogalacto-
side (IPTG) were purchased from Takara Biotechnology Co.,
Ltd., goat anti-rabbit HRP-IgG antibodies were purchased
from the Boster Company, sodium dodecyl sulfate (SDS),
ammonium persulfate (APS), N,N,N,N-tetramethylethylenedi-
amine (TEMED) is from the AMRESCO company, electro-
phoresis grade acryl amide and Tris-base were from
BioSharp, and N,N-methylene-bis-acrylamide was from
Gibco.
2.3. Bacteria growth and DNA extraction
Salmonella enterica serovar Enteritidis was cultured over night
at 37 C with vigorous agitation and then DNA was extracted.
FimA gene (6949132) was ampliﬁed by an upper primer with
NdeI restriction enzyme site: 5’-CGC CATATG AAA CAT
AAA TTA ATG ACC TCT A-3’ and lower primer with NotI
and BamHI restriction enzymes site: 5’-TCG GCG GCC GCG
GAT CCT TCG TAT TTC ATG ATA AAG GTG-3’. PCR
was carried out in a total volume of 25 ll containing 2.5 ll
DNA template, 1.5 ll of 2.5 mM dNTP mixture, 2.5 ll of
10 · PCR buffer, 1 ll upper primer, 0.5 ll lower primer,
0.5 ll Ex Taq polymerase and 16.5 ll sterilized distilled water.
PCR conditions were initial denaturation at 94 C for 4 min,
followed by 30 cycles at 94 C for 1 min, annealing at 56 C
for 1 min and extended at 72 C for 1 min, and ﬁnally the
PCR product was extended at 72 C for 10 min. The 550 bp
of FimA gene was excised from the gel and puriﬁed using
DNA puriﬁcation kit. Puriﬁed product was then cloned into
pMD18-T simple vector and transformed into E. coli DH5a
competent cells. The E. coli DH5a carrying recombinant plas-
mid (pMD18-T + FimAgene) was grown on LB plates con-
taining 100 lg/ml ampicillin at 37 C overnight, and the
single clone was grown in 5 ml LB broth plus ampicillin
(100 lg/ml) at 37 C to OD600 of 0.4–0.5. Recombinant plas-
mids were extracted and digested by restriction enzyme and
sequenced.
2.4. Construction of recombinant protein
Recombinant plasmids pMD18-T-FimA and pCold-TF vectors
were digested with NdeI and BamHI restriction enzymes. Both
ﬁmA gene and pCold-TF expression vector were recovered from
the gel using the agarose gel DNApuriﬁcation kit. Puriﬁed ﬁmA
DNAwas cloned into pCold-TF expression vector (Fig. 1). The
recombinant pCold-TF-ﬁmA was transformed into the E. coli
DH5a competent cells; positive clones were selected and
determined by restriction enzyme NdeI and BamHI. Clones of
Figure 1 pCold TF DNA plasmid map.
Cloning and expression of FimA-c3d recombinant protein 57the pUC-C3dn plasmid generated according to strategy of
Dempsey et al. [2] were gifted from Drs. Leonard J Bello and
Lingshu Wang, University of Pennsylvania, USA. Each C3d
was connected with a linker sequence encoding glycine/serine
repeats GS (G4S)2 GS, of which potential proteolytic cleavage
sites were mutated by BamH1 and BglII fusion to mutate an
arginine to a glycine. The plasmids were digested with BamHI
and BglII to release the BLc3d, BLc3d2 and BLc3d3 fragments,
and pCold-TF-ﬁmA clone was digested with BamHI. The
digested products were recovered from the gel using the agarose
gel DNA puriﬁcation kit, then the BLc3d, BLc3d2 and BLc3d3
fragments were respectively cloned into the pCold-TF-ﬁmA.
The recombinant DNA was transformed into the E. coli
DH5a competent cells and the positive clones were selected
and determined by PCR and restriction enzyme analysis.
2.5. Recombinant protein expression
Two microliters of each of pCold-TF-ﬁmA, pCold-TF-ﬁmA-
BLc3d, pCold-TF-ﬁmA-BLc3d2 and pCold-TF-ﬁmA-BLc3d3
plasmid was used to transform 200 ll E. coli BL21 (DE3).
The E. coli BL21 (DE3) carrying pCold-TF-ﬁmA-BLc3d was
grown on LB plates containing 100 lg/ml ampicillin at 37 C
overnight. Then the single clone was grown in 5 ml LB broth
plus ampicillin (50 lg/ml) at 37 C to OD600 of 0.4–0.5. After
standing for 30 min at 15 C, the culture was split into two ali-
quots. One was induced by IPTG to a ﬁnal concentration of
0.1 mmol/L at 15 C for 24 h and the other un-induced was
considered as control. Cells harvested were lysed by sonication
and subjected to 8% SDS–PAGE. The protein on 8% SDS–
PAGE was transferred to nitrocellulose membrane (0.35 mA/
cm2).The membrane was blocked with 10% nonfat dry milk
and incubated with a primary antibody (Type 1 ﬁmbriae poly-
clonal (Rabbit) antibody) (1:100) and with a secondary anti-
body (Goat Anti-Rabbit IgG) (1:1500). The recombinant
proteins were separately puriﬁed by Ni-TED (tris-carboxy-
methyl ethylene diamine) immobilized metal iron afﬁnity
chromatography (IMAC).
3. Results and discussion
Molecular adjuvant C3d can be linked to different antigens,
and effectively enhances the titer and life-span of speciﬁcantibodies against these antigens [20,15]. Comparison of the
C3d sequences of human (hC3d), mouse (mC3d) and bovine
(boC3d) showed 84.1% amino acid homology between hC3d
and mC3d and 80.5% homology between hC3d and boC3d,
they either showed the function of immune adjuvant in the
mammalian model [37]. Certain proteins are not produced efﬁ-
ciently at 37 C, while they can be overproduced in large quan-
tities at low temperatures by using cold-inducible promoters,
for example, the promoter of cspA, encoding the major cold
shock protein of E. coli [22]. In the present study soluble
Fim A protein fused to C3d was expressed in prokaryote
expression vector. The ﬁmA gene was ampliﬁed by PCR using
a pair of primers and the DNA template from Salmonella ent-
erica serovar Enteritidis standard strain SD-2 genomic DNA.
FimA gene was digested and cloned into pCold-TF expression
vector to construct recombinant plasmid pCold-ﬁmA, which
was conﬁrmed by restriction enzymes and sequencing. The dif-
ferent copies of mC3d, mC3d2 and mC3d3 were obtained
through the digestion of recombinant plasmids pUC-mC3d,
pUC-mC3d2 and pUC-mC3d3, and were cloned into the
recombinant plasmid pCold-ﬁmA to construct the recombi-
nant plasmids, i.e. pCold-ﬁmA-mC3d, pCold-ﬁmA-mC3d2
and pCold-ﬁmA-mC3d3. The fusion proteins were optimally
induced by IPTG at 15 C for 24 h, and were expressed in
E. coli BL21 (DE3). A variety of methods have been developed
for including protein production at low temperature, and for
fusion protein expression using soluble protein tags [11]. When
an E. coli culture growing at 37 C is shifted to low tempera-
ture, cell growth stops temporarily. During this growth lag
period, called the acclimation phase, the synthesis of most cel-
lular proteins is sharply reduced, whereas a speciﬁc set of pro-
teins termed ‘‘cold shock proteins’’ are induced [35,33]. Among
these cold shock-inducible proteins, CspA is the major cold
shock protein in E. coli [7], which can be induced to a level
of 10 · 106 molecules/cell [1,34]. CspA has been implicated to
be a negative regulator of its own gene expression, because
in a strain with a deletion mutation of the cspA coding
sequence, the amount of the truncated cspA mRNA was
much more than that in its parental strain, and the production
of such truncated cspA mRNA was prolonged in the mutant
cells [36].
The pCold vector used in the present study contains the
promoter of the cold shock-inducible gene for the major cold
shock protein CspA and the gene’s 134-base 5 untranslated
region, allowing a very high level of expression of a cloned
gene upon cold shock [23]. This vector also contains a lac oper-
ator downstream of the cspA promoter so that the expression
of a cloned gene can be tightly regulated not only by temper-
ature but also by lac inducers such as isopropyl-b-D-1-thioga-
lactopyranoside (IPTG) [14]. TF in pCold vector has a
‘maintenance and repair’ function as it helps protein synthesis
and folding to continue at low temperature [12]. It accelerates
proline-limited steps in protein folding with a very high efﬁ-
ciency. In addition, it associates with ribosomes and inﬂuences
the folding of newly formed protein chains [19]. Although the
pCold vector is designed for the production of proteins at
15 C, the CspA promoter is also active at 37 C and some pro-
teins can be produced in high yields at room temperature with
the pCold vector [14].
The expressed proteins with the molecular weight of
70 kDa, 100 kDa, 130 kDa and 160 kDa, respectively, were
conﬁrmed by SDS–PAGE (Fig. 2). The antigenicity of the
58 H.H. Musa et al.recombinant proteins expressing FimA was demonstrated by
Western blotting with the goat against rabbit polyclonal anti-
body of type I ﬁmbriae (Fig. 3). The recombinant proteins
were separately puriﬁed by Ni-TED (tris-carboxymethyl ethyl-
ene diamine) immobilized metal iron afﬁnity chromatography
(IMAC) (Fig. 4). Kobayashi et al. [14] demonstrated that the
expression and solubility levels of a number of human proteins
are signiﬁcantly improved when these proteins are expressed as
fusions with the NTDs of protein S by using pCold vector [14].
The pCold-GST expression system was applied to express 10
proteins that could not be expressed using conventional
E. coli expression method, and nine of these proteins were suc-
cessfully obtained in the soluble fraction [11]. Hayashi and
Kojima [11] suggested that the pCold-GST expression systemFigure 2 SDS–PAGE for recombinant proteins (1) FimA; (2)
Control vector; (3) FimA-mC3d3; (4) FimA-mC3d2; (5) FimA-
mC3d; and M. Low (Molecular weight range: 14.3–97.2 kDa).
Figure 3 Western blotting of the recombinant proteins (1)
FimA; (2) FimA-mC3d; (3) FimA-mC3d2; (4) FimA-mC3d3; and
M. Pre-stained Low (Molecular weight range: 14.3–97.2 kDa).
Figure 4 SDS–PAGE of puriﬁed recombinant proteins (1)
FimA; (2) FimA-mC3d; (3) FimA-mC3d2; (4) FimA-mC3d3;
and M. High (Molecular weight range: 44.3–200 kDa).can be utilized to improve the expression and puriﬁcation of
various proteins [11]. This new technology can also be used
for the analysis of protein–protein interactions and for the
structural study of proteins which are difﬁcult to express or
are insoluble [14]. C3d could enhance antibody responses
directed toward a speciﬁc antigen encoded by a DNA vaccine
[26]. Three copies of murine C3d could dramatically enhance
antibody responses to a speciﬁc antigen, being 100-fold more
effective than incomplete Freunds adjuvant [2,18]. Wang [28]
reported that the bovine homologue of C3d (boC3d) coupled
to the E2 envelope protein of bovine viral diarrhea virus
greatly enhanced immunogenicity in mice. Similarly, chicken
C3d-P29 linked to the F gene of Newcastle disease virus
(NDV) enhanced immunogenicity in chickens [16]. Therefore,
in the present study we conclude that antigen conjugated with
mC3d can be functionally expressed in prokaryotic vectors.Acknowledgements
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